-
Mashup Score: 1T-DXd in HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer DESTINY-Gastric02 - The ASCO Post - 10 month(s) ago
By Matthew Stenger Posted: 7/27/2023 12:05:00 PM Last Updated: 6/27/2023 11:36:20 AM In the phase II DESTINY-Gastric02 trial reported in The Lancet Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) was active in patients with HER2-positive advanced gastric…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Study Reveals Link Between Obesity and Gastric Cancer Aggressiveness - The ASCO Post - 12 month(s) ago
Extracellular vesicles from adipocytes offer new insights and potential therapeutic targets. A pioneering study from Israel has shed new light on the link between obesity and the aggressiveness of gastric cancer while demonstrating potential therapeutic targets for the disease. Results of the translational research, presented during the…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study Reveals Link Between Obesity and Gastric Cancer Aggressiveness https://t.co/Ad7Sm2BDdn #stcsm #gastriccancer #obesity #oncology #SSO23
-
-
Mashup Score: 0
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a Phase II trial (NCT05190445) of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥Geoffrey Ku of @MSKCancerCenter discusses findings from a Phase II trial of cinrebafusp alfa, a bispecific fusion protein targeting HER2 & 4-1BB, in patients with HER2-positive gastric/GEJ adenocarcinoma. Watch 👉 https://t.co/nzJ3cganYF👈 #AACR23 @AACR #ESOCsm #STCsm
-
-
Mashup Score: 0GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset - The ASCO Post - 1 year(s) ago
In the first-line setting, the monoclonal antibody zolbetuximab in combination with chemotherapy extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive, HER2-negative, locally advanced or metastatic gastric adenocarcinoma. This regimen is now positioned as a new standard of care in a subset of patients, according to the results of the global phase III GLOW trial, presented in…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset https://t.co/fziY7rWevl #ASCOPlenarySeries #stcsm #gastriccancer #oncology #immunotherapy
-
-
Mashup Score: 0Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma - 1 year(s) ago
The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma #stcsm #esocsm https://t.co/KasBQpTDKR
-
-
Mashup Score: 1VJOncology – The video journal of oncology - 1 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#GDUGI2023 may be over but there’s still plenty of gastrointestinal oncology to catch up on 📽️📝 Find updates and highlights of all things #Cancer and oncology research at https://t.co/ys1d8pDAKO 💻 @GreatDebatesCME #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/IE9LVun3q0
-
-
Mashup Score: 0
The FDA has accepted a biologics license application for a proposed trastuzumab biosimilar. The therapy is being considered as adjuvant therapy for certain HER2-overexpressing cancers.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has accepted a biologics license application for a proposed trastuzumab biosimilar. The therapy is being considered as adjuvant therapy for certain HER2-overexpressing cancers. #bcsm #gastriccancer #stcsm #oncology #nursing https://t.co/GlnCFITvac
-
-
Mashup Score: 0Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer - The ASCO Post - 1 year(s) ago
By Matthew Stenger Posted: 4/11/2023 10:19:00 AM Last Updated: 4/11/2023 11:08:44 AM In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer https://t.co/f5D4wOrmhu #stcsm #gastriccancer #oncology
-
-
Mashup Score: 0
The FDA has accepted a biologics license application for a proposed trastuzumab biosimilar. The therapy is being considered as adjuvant therapy for certain HER2-overexpressing cancers.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Trastuzumab Biosimilar BLA Accepted for HER2+ Breast Cancer and Gastric Cancer #bcsm #gastriccancer #stcsm #oncology #nursing https://t.co/tWeTByojvy
-
-
Mashup Score: 0AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20) - 1 year(s) ago
This phase Ib/II study was conducted to determine the safety and efficacy of AZD8186 and paclitaxel combination in patients with metastatic or recurrent gastric
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This phase Ib/II study showed that the combination of #AZD8186 and #paclitaxel was well-tolerated but had limited clinical efficacy in patients with metastatic/recurrent #GastricCancer with PTEN loss or PTEN/PIK3CB gene abnormality. #STCSM https://t.co/kschE5wlDV https://t.co/2YnfynZO6B
-
T-DXd in HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: DESTINY-Gastric02 https://t.co/oLLJPOdOVB #stcsm #GEJcancer #immunotherapy #oncology